Home › Funds › JOHNSON & JOHNSON › PTGX

JOHNSON & JOHNSON position in PTGX

PROTAGONIST THERAPEUTICS INC · Health Care

JOHNSON & JOHNSON reported holding 2,449,183 shares of PTGX (PROTAGONIST THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$345.1M, representing 45.30% of its reported portfolio and ranking #1 among its reported holdings. JOHNSON & JOHNSON has disclosed PTGX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)2.45M sh
Reported value held$345.07M
Portfolio Weight45.30%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How JOHNSON & JOHNSON's PTGX position evolved

JOHNSON & JOHNSON first disclosed a stake in PTGX in Q3 2023 at 2,449,183 shares (US$40.9M). The position peaked in Q3 2026 at 2,449,183 shares, worth US$345.1M. Across 13 filings, JOHNSON & JOHNSON held the position steady without any share-count change. The most recent filing (Q3 2026) shows 2,449,183 shares valued at US$345.1M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.45M $40.85M New
Q4 2023 2.45M $56.16M Hold
Q1 2024 2.45M $70.85M Hold
Q2 2024 2.45M $84.86M Hold
Q3 2024 2.45M $110.21M Hold
Q4 2024 2.45M $94.54M Hold
Q1 2025 2.45M $118.44M Hold
Q2 2025 2.45M $136.40M Hold
Q3 2025 2.45M $162.70M Hold
Q4 2025 2.45M $213.91M Hold
Q1 2026 2.45M $258.14M Hold
Q2 2026 2.45M $300.22M Hold
Q3 2026 2.45M $345.07M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PTGX and 13F data

PTGX (PROTAGONIST THERAPEUTICS INC) is a Health Care company. 50 other funds we track also report a position in PTGX — the largest reported positions include Farallon Capital Management (US$778.2M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$778.2M), RTW INVESTMENTS, LP (US$620.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PTGX

All PTGX fund holders →

FAQ

How long has JOHNSON & JOHNSON held PTGX?

JOHNSON & JOHNSON has disclosed PTGX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is JOHNSON & JOHNSON's current position in PTGX?

As of Q3 2026, JOHNSON & JOHNSON holds 2.45M shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $345.07M, representing 45.30% of its reported portfolio and ranking #1.

Has JOHNSON & JOHNSON been buying or selling PTGX?

In the latest 13F filing (Q3 2026), JOHNSON & JOHNSON held unchanged its position in PTGX. The position peaked in Q3 2026 at 2.45M shares.

Which other funds hold PTGX?

Other major institutional holders of PTGX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., RTW INVESTMENTS, LP, among 50 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.